Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Investor Presentation Corporate Fact Sheet

Latest News

IMUNON to Participate in Upcoming Investor Conferences

October 8, 2026

IMUNON Converts $1.2 Million of Debt-to-Equity

September 29, 2026

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

September 24, 2026

Financial Events

Presentation at the 2026 ThinkEquity Conference

October 15, 2026 at 1:30 PM EDT

Oncology Panel Presenation at the Maxim Growth Summit 2026

October 14, 2026 at 9:00 AM EDT